Telehealth providers Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Feed
13:22
Sep 15
Sep 15
DTC pharma access channel is expanding
A parallel direct-to-consumer access channel is emerging in biopharma: patients can initiate treatment, obtain prescriptions digitally through telehealth, and fill through non-traditional cash-pay channels. This model is most viable for self-administered drugs with limited in-person infrastructure, lower price points or coverage gaps, and no REMS restrictions. Manufacturers already sell over 25 branded drugs this way, and Morgan Stanley estimates a $26B peak US DTC opportunity, about 3% of branded pharma spend, expanding as more self-administered products launch.
HIGH
About Telehealth providers Investor Commentary
Across the available history and selected sources, Buzzberg tracks Telehealth providers across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: Terence Flynn.